| Q35730155 | "Down syndrome: an insight of the disease" |
| Q37624999 | "I think we've got too many tests!": Prenatal providers' reflections on ethical and clinical challenges in the practice integration of cell-free DNA screening. |
| Q40223085 | 'Hope for safe prenatal gene tests'. A content analysis of how the UK press media are reporting advances in non-invasive prenatal testing |
| Q36423067 | 14 Years of Polish Experience in Non-Invasive Prenatal Blood Group Diagnosis |
| Q90164359 | 46,XX DSD due to Androgen Excess in Monogenic Disorders of Steroidogenesis: Genetic, Biochemical, and Clinical Features |
| Q92620044 | A Cell-free DNA Barcode-Enabled Single-Molecule Test for Noninvasive Prenatal Diagnosis of Monogenic Disorders: Application to β-Thalassemia |
| Q35893839 | A Method to Quantify Cell-Free Fetal DNA Fraction in Maternal Plasma Using Next Generation Sequencing: Its Application in Non-Invasive Prenatal Chromosomal Aneuploidy Detection. |
| Q98291733 | A Novel Graphic-Aided Algorithm (gNIPT) Improves the Accuracy of Noninvasive Prenatal Testing |
| Q40201029 | A Pilot Study of Noninvasive Prenatal Diagnosis of Alpha- and Beta-Thalassemia with Target Capture Sequencing of Cell-Free Fetal DNA in Maternal Blood |
| Q54986845 | A Profile of Dennis Lo, DM, DPhil, FRCP, FRCPath, FRS. |
| Q92882112 | A cell-free DNA metagenomic sequencing assay that integrates the host injury response to infection |
| Q88207921 | A commentary on comparison of the performance of Ion Torrent chips in noninvasive prenatal trisomy detection |
| Q38837429 | A de novo duplication of chromosome 9q34.13-qter in a fetus with Tetralogy of Fallot Syndrome |
| Q48178985 | A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications |
| Q46306454 | A historical and evolutionary perspective on the biological significance of circulating DNA and extracellular vesicles |
| Q38170863 | A historical and practical review of first trimester aneuploidy screening |
| Q34661748 | A low-cost efficient multiplex PCR for prenatal sex determination in bovine fetus using free fetal DNA in maternal plasma |
| Q45049473 | A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing |
| Q92830732 | A method for noninvasive prenatal diagnosis of monogenic autosomal recessive disorders |
| Q50773159 | A monoclonal antibody with potential for aiding non-invasive prenatal diagnosis: utility in screening of pregnant women at risk of preeclampsia. |
| Q55266945 | A new biosensor for noninvasive determination of fetal RHD status in maternal blood of RhD negative pregnant women. |
| Q37108873 | A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device |
| Q37433730 | A new method for non-invasive prenatal diagnosis of Down syndrome using MeDIP real time qPCR. |
| Q51346655 | A new non-invasive prenatal diagnosis of Down syndrome through epigenetic markers and real-time qPCR. |
| Q79756571 | A non-invasive test for prenatal diagnosis based on fetal DNA present in maternal blood: a preliminary study |
| Q60046302 | A novel approach to stabilize fetal cell-free DNA fraction in maternal blood samples for extended period of time |
| Q42372436 | A prospective clinical trial to compare the performance of dried blood spots prenatal screening for Down's syndrome with conventional non-invasive testing technology |
| Q34613043 | A rapid method for simultaneous screening of multi-gene mutations associated with hearing loss in the Korean population |
| Q37703889 | A short history of sonography in obstetrics and gynaecology |
| Q91272659 | A view on drug resistance in cancer |
| Q36618056 | Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients |
| Q34862292 | Acceptability of prenatal testing and termination of pregnancy in Pakistan |
| Q92128109 | Adaptable Model Parameters in Non-Invasive Prenatal Testing Lead to More Stable Predictions |
| Q48609420 | Advances in prenatal screening: the ethical dimension. |
| Q36508665 | Advances in the medical research and clinical applications on the plasma DNA |
| Q34927319 | Akonni TruTip(®) and Qiagen(®) methods for extraction of fetal circulating DNA--evaluation by real-time and digital PCR. |
| Q36143042 | An Advanced Model to Precisely Estimate the Cell-Free Fetal DNA Concentration in Maternal Plasma |
| Q37115493 | An Optimized Method for Accurate Fetal Sex Prediction and Sex Chromosome Aneuploidy Detection in Non-Invasive Prenatal Testing |
| Q50655026 | An SNP panel for the analysis of paternally inherited alleles in maternal plasma using ion Torrent PGM. |
| Q36157384 | An adaptive detection method for fetal chromosomal aneuploidy using cell-free DNA from 447 Korean women |
| Q36695389 | An easy test but a hard decision: ethical issues concerning non-invasive prenatal testing for autosomal recessive disorders |
| Q64120626 | An efficient method for noninvasive prenatal diagnosis of fetal trisomy 13, trisomy 18, and trisomy 21 |
| Q51569562 | An emulsion system based on a chip polymerase chain reaction. |
| Q64055782 | An enrichment method to increase cell-free fetal DNA fraction and significantly reduce false negatives and test failures for non-invasive prenatal screening: a feasibility study |
| Q77326117 | An innate view of human pregnancy |
| Q50751059 | An innovative test for non-invasive Kell genotyping on circulating fetal DNA by means of the allelic discrimination of K1 and K2 antigens. |
| Q38364898 | An update on current prenatal testing options: first trimester and noninvasive prenatal testing. |
| Q37508836 | An update to 21-hydroxylase deficient congenital adrenal hyperplasia |
| Q36173927 | Analysis of cell-free fetal DNA in maternal blood for detection of trisomy 21, 18 and 13 in a general pregnant population and in a high risk population - a systematic review and meta-analysis |
| Q54677058 | Analysis of cell-free fetal DNA in plasma and serum of pregnant women. |
| Q52724596 | Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. |
| Q38889509 | Analysis of false-positive results of fetal RHD typing in a national screening program reveals vanishing twins as potential cause for discrepancy |
| Q90724412 | Analysis of fetal DNA in maternal plasma with markers designed for forensic DNA mixture resolution |
| Q26778480 | AngiomiRs: Potential Biomarkers of Pregnancy's Vascular Pathologies |
| Q73290722 | Apoptosis in fetal nucleated erythrocytes circulating in maternal blood |
| Q40440447 | Application of fetal DNA detection in maternal plasma: a prenatal diagnosis unit experience. |
| Q80138259 | Application of fetal DNA in maternal plasma in noninvasive prenatal diagnosis |
| Q81507580 | Application of maternal plasma DNA analysis for noninvasive prenatal diagnosis of Hb E-beta-thalassemia |
| Q51320246 | Application of polymerase chain reaction for fetal gender determination using cervical mucous secretions in the cow. |
| Q31011773 | Application of risk score analysis to low-coverage whole genome sequencing data for the noninvasive detection of trisomy 21, trisomy 18, and trisomy 13. |
| Q35594672 | Applications of DNA-based assays in blood group antigen and antibody identification |
| Q33904199 | Applications of molecular biology techniques to transfusion medicine |
| Q34209281 | Assessment of Foetal DNA in Maternal Blood - A Useful Tool in the Hands of Prenatal Specialists |
| Q53060571 | Assessment of free fetal DNA concentration in maternal plasma during the first trimester of pregnancy: comparative study between EDTA and PPT tubes - pilot study. |
| Q92589516 | Assessment of laboratories offering cell-free (cf) DNA screening for Down syndrome: results of the 2018 College of American Pathology External Educational Exercises |
| Q33990071 | Attitudes of mothers of children with down syndrome towards noninvasive prenatal testing |
| Q47636094 | Attitudes of parents of Klinefelter boys and pediatricians towards neonatal screening and fertility preservation techniques in Klinefelter syndrome. |
| Q59795751 | Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure |
| Q38830153 | Benefits and limitations of prenatal screening for Prader-Willi syndrome |
| Q38101277 | Benefits and limitations of whole genome versus targeted approaches for noninvasive prenatal testing for fetal aneuploidies |
| Q35756049 | Biochemical markers for prediction of preclampsia: review of the literature. |
| Q37691066 | Bioinformatics Approaches for Fetal DNA Fraction Estimation in Noninvasive Prenatal Testing |
| Q35738581 | Bisulfite Conversion of DNA: Performance Comparison of Different Kits and Methylation Quantitation of Epigenetic Biomarkers that Have the Potential to Be Used in Non-Invasive Prenatal Testing |
| Q53748681 | Blood fetal microchimerism in primary biliary cirrhosis. |
| Q46306526 | Blood laboratory testing for early prediction of preeclampsia: chasing the finish line or at the starting blocks? |
| Q64933972 | Blood-based DNA Methylation Biomarkers for Early Detection of Colorectal Cancer. |
| Q35054648 | Body fluid derived exosomes as a novel template for clinical diagnostics |
| Q57663987 | Boy or girl? The implications of using cell-free fetal DNA to decide fetal sex |
| Q38977149 | COFFEE: control-free noninvasive fetal chromosomal examination using maternal plasma DNA. |
| Q52883296 | COLD-PCR and microarray: two independent highly sensitive approaches allowing the identification of fetal paternally inherited mutations in maternal plasma. |
| Q37406706 | Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents |
| Q59091333 | Cancer biomarkers: Written in blood |
| Q56765605 | Candidate epigenetic biomarkers for non-invasive prenatal diagnosis of Down syndrome |
| Q90675913 | Cell-Free DNA Release by Mouse Fetal Membranes |
| Q38928166 | Cell-Free DNA Screening: Complexities and Challenges of Clinical Implementation. |
| Q47142145 | Cell-Free DNA in Oncology: Gearing up for Clinic |
| Q89660275 | Cell-Free Fetal DNA Increases Prior to Labor at Term and in a Subset of Preterm Births |
| Q39006810 | Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis |
| Q57557794 | Cell-Free Fetal DNA in Maternal Plasma during Physiological Single Male Pregnancies: Methodology Issues and Kinetics |
| Q38541725 | Cell-Free Fetal DNA, Telomeres, and the Spontaneous Onset of Parturition |
| Q92256909 | Cell-Free Nucleic Acids and their Emerging Role in the Pathogenesis and Clinical Management of Inflammatory Bowel Disease |
| Q35589313 | Cell-free DNA and RNA in plasma as new tools for molecular diagnostics |
| Q92590013 | Cell-free DNA donor fraction analysis in pediatric and adult heart transplant patients by multiplexed allele-specific quantitative PCR: Validation of a rapid and highly sensitive clinical test for stratification of rejection probability |
| Q47305758 | Cell-free DNA fragment-size distribution analysis for non-invasive prenatal CNV prediction |
| Q35694161 | Cell-free DNA fragmentation patterns in amniotic fluid identify genetic abnormalities and changes due to storage |
| Q47313732 | Cell-free DNA in maternal plasma: is it all a question of size? |
| Q100634927 | Cell-free DNA in plasma as an essential immune system regulator |
| Q40269661 | Cell-free DNA levels in pregnancies at risk of sickle-cell disease and significant ethnic variation |
| Q90629442 | Cell-free DNA levels of twins and sibling pairs indicate individuality and possible use as a personalized biomarker |
| Q33806881 | Cell-free DNA release by mouse placental explants |
| Q38509263 | Cell-free DNA versus intact fetal cells for prenatal genetic diagnostics: what does the future hold? |
| Q38371846 | Cell-free Fetal Nucleic Acid Identifier Markers in Maternal Circulation |
| Q33587517 | Cell-free and intracellular nucleic acids: new non-invasive biomarkers to explore male infertility |
| Q46670174 | Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker |
| Q37169269 | Cell-free fetal DNA and non-invasive prenatal diagnosis |
| Q35110814 | Cell-free fetal DNA and pregnancy-related complications (review) |
| Q50356518 | Cell-free fetal DNA and spontaneous preterm birth. |
| Q35966472 | Cell-free fetal DNA in maternal blood: kinetics, source and structure |
| Q28241617 | Cell-free fetal DNA in maternal plasma: an important advance to link fetal genetics to obstetric ultrasound |
| Q36152745 | Cell-free fetal DNA in the maternal circulation and its future uses in obstetrics |
| Q51042727 | Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies. |
| Q36321452 | Cell-free fetal DNA testing for fetal aneuploidy and beyond: clinical integration challenges in the US context |
| Q35434562 | Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation |
| Q42393162 | Cell-free fetal DNA: the new tool in fetal medicine |
| Q39778751 | Cell-free fetal nucleic acids as prenatal biomarkers |
| Q34768792 | Cell-free fetal nucleic acids in amniotic fluid |
| Q91773787 | Cell-free mitochondrial DNA in human follicular fluid: a promising bio-marker of blastocyst developmental potential in women undergoing assisted reproductive technology |
| Q58128922 | Challenges in Prenatal Treatment with Dexamethasone |
| Q48285694 | Challenges in non-invasive prenatal screening for sub-chromosomal copy number variations using cell-free DNA. |
| Q38959581 | Changing to NIPT as a first-tier screening test and future perspectives: opinions of health professionals |
| Q93910293 | Chorionic villus sampling versus early amniocentesis |
| Q35667141 | Chromosomal Mosaicism in Human Feto-Placental Development: Implications for Prenatal Diagnosis |
| Q36731622 | Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases |
| Q37358895 | Circulating C19MC microRNAs in preeclampsia, gestational hypertension, and fetal growth restriction |
| Q37690677 | Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. |
| Q98735793 | Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine |
| Q99591387 | Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application |
| Q35023094 | Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications |
| Q91893726 | Circulating DNA, a Potentially Sensitive and Specific Diagnostic Tool for Future Medicine |
| Q43816234 | Circulating RNA coding genes regulating apoptosis in maternal blood in severe early onset fetal growth restriction and pre-eclampsia. |
| Q47163092 | Circulating cell-free DNA concentration and DNase I activity of peripheral blood plasma change in case of pregnancy with intrauterine growth restriction compared to normal pregnancy. |
| Q52601844 | Circulating cell-free DNA for non-invasive cancer management. |
| Q42384372 | Circulating cell-free DNA in hematological malignancies |
| Q34250874 | Circulating cell-free DNA levels increase variably following chorionic villus sampling. |
| Q57178025 | Circulating cell-free nucleic acids: characteristics and applications |
| Q34428197 | Circulating fetal DNA in maternal plasma |
| Q26825718 | Circulating microRNAs as clinical biomarkers in the predictions of pregnancy complications |
| Q58035393 | Circulating nucleic acids as a new diagnostic tool |
| Q36790198 | Circulating nucleic acids in plasma and serum: applications in diagnostic techniques for noninvasive prenatal diagnosis |
| Q58570442 | Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test |
| Q33572406 | Clinical Utility of Non-Invasive Prenatal Screening from Maternal Blood |
| Q51506259 | Clinical application of fetal sex determination using cell-free fetal DNA in pregnant carriers of X-linked genetic disorders. |
| Q43787267 | Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population. |
| Q64912141 | Clinical application of noninvasive prenatal screening for sex chromosome aneuploidies in 50,301 pregnancies: initial experience in a Chinese hospital. |
| Q54285680 | Clinical evaluations of cell-free fetal DNA quantities in pre-eclamptic pregnancies. |
| Q36353229 | Clinical utility of noninvasive fetal trisomy (NIFTY) test--early experience. |
| Q39387768 | Clinical, social and ethical issues associated with non-invasive prenatal testing for aneuploidy |
| Q44454430 | Clinically relevant genetic advances in endocrinology. |
| Q90505053 | Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation |
| Q92642536 | Combination of Fetal Fraction Estimators Based on Fragment Lengths and Fragment Counts in Non-Invasive Prenatal Testing |
| Q37504505 | Commercial landscape of noninvasive prenatal testing in the United States |
| Q83557679 | Community Corner: Opening the Pandora's box of prenatal genetic testing |
| Q35693396 | Comparative Transcriptome Analysis of Cell-Free Fetal RNA from Amniotic Fluid and RNA from Amniocytes in Uncomplicated Pregnancies. |
| Q54499182 | Comparison of PCR methods for detecting fetal RhDin maternal plasma. |
| Q51514162 | Comparison of the performance of Ion Torrent chips in noninvasive prenatal trisomy detection. |
| Q36003623 | Comparison of two high-throughput semiconductor chip sequencing platforms in noninvasive prenatal testing for Down syndrome in early pregnancy |
| Q34921290 | Complete genes may pass from food to human blood. |
| Q24614223 | Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline |
| Q38586467 | Considerations of red blood cell molecular testing in transfusion medicine |
| Q47308150 | Cost-effective and accurate method of measuring fetal fraction using SNP imputation |
| Q38932336 | Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis |
| Q43448023 | Costs and benefits of non-invasive fetal RhD determination |
| Q36014447 | Could Digital PCR Be an Alternative as a Non-Invasive Prenatal Test for Trisomy 21: A Proof of Concept Study. |
| Q41126649 | Count-based size-correction analysis of maternal plasma DNA for improved noninvasive prenatal detection of fetal trisomies 13, 18, and 21 |
| Q88990659 | Current approaches on non-invasive prenatal diagnosis: Prenatal genomics, transcriptomics, personalized fetal diagnosis |
| Q51265143 | Current controversies in prenatal diagnosis 1: NIPT for chromosome abnormalities should be offered to women with low a priori risk. |
| Q37849710 | Current controversies in prenatal diagnosis 2: Down syndrome screening: is ultrasound better than cell-free nucleic acids in maternal blood? |
| Q53674441 | Current controversies in prenatal diagnosis 3: industry drives innovation in research and clinical application of genetic prenatal diagnosis and screening. |
| Q38740942 | Current status of non-invasive prenatal testing in Japan. |
| Q47797945 | Current, Emerging, and Future Applications of Digital PCR in Non-Invasive Prenatal Diagnosis |
| Q47769720 | Cytogenetic highlights and transitions |
| Q37222110 | Cytogenetics and the evolution of medical genetics |
| Q39581690 | DASAF: An R Package for Deep Sequencing-Based Detection of Fetal Autosomal Abnormalities from Maternal Cell-Free DNA. |
| Q33627712 | DNA Sequence Analysis in Clinical Medicine, Proceeding Cautiously |
| Q50650841 | DNA methylome profiling of maternal peripheral blood and placentas reveal potential fetal DNA markers for non-invasive prenatal testing. |
| Q34029044 | DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study |
| Q36632942 | De novo mutations in neurological and psychiatric disorders: effects, diagnosis and prevention |
| Q40007043 | Decision-making for non-invasive prenatal testing for Down syndrome: Hong Kong Chinese women's preferences for individual vs relational autonomy |
| Q53516393 | Delivering noninvasive prenatal testing in a clinical setting using semiconductor sequencing platform. |
| Q38550197 | Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids |
| Q57079526 | Detecting fetal subchromosomal aberrations by MPS: an unexpected discrepancy between amniocyte DNA and ccffDNA |
| Q35415027 | Detection and quantification of male-specific fetal DNA in the serum of pregnant cynomolgus monkeys (Macaca fascicularis). |
| Q64899007 | Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). |
| Q35199886 | Detection of Y STR markers of male fetal dna in maternal circulation |
| Q48202036 | Detection of Y chromosome material in a 46,XX male with SRY translocation: novel application of cell-free fetal DNA testing. |
| Q56001883 | Detection of Y chromosome-specific DNA in the plasma and urine of pregnant women using nested polymerase chain reaction |
| Q54571358 | Detection of a paternally inherited fetal mutation in maternal plasma by the use of automated sequencing. |
| Q102152274 | Detection of cell-free foetal DNA fraction in female-foetus bearing pregnancies using X-chromosomal insertion/deletion polymorphisms examined by digital droplet PCR |
| Q36454528 | Detection of complex deletions in chromosomes 13 and 21 in a fetus by noninvasive prenatal testing |
| Q77429872 | Detection of fetal RHD-specific sequences in maternal plasma |
| Q37611040 | Detection of fetal RhD gene from maternal blood |
| Q35958986 | Detection of fetal cell-free DNA in maternal plasma for Down syndrome, Edward syndrome and Patau syndrome of high risk fetus |
| Q50204931 | Detection of fetal duplication 16p11.2q12.1 by next-generation sequencing of maternal plasma and invasive diagnosis |
| Q33702225 | Detection of fetal epigenetic biomarkers through genome-wide DNA methylation study for non-invasive prenatal diagnosis |
| Q91955816 | Detection of microbial cell-free DNA in maternal and umbilical cord plasma in patients with chorioamnionitis using next generation sequencing |
| Q45234240 | Detection of microchimerism by PCR is a function of amplification strategy |
| Q36983015 | Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. |
| Q34078379 | Detection of the placental epigenetic signature of the maspin gene in maternal plasma. |
| Q34921561 | Determination of fetal chromosome aberrations from fetal DNA in maternal blood: has the challenge finally been met? |
| Q50707964 | Development and application of a real-time quantitative PCR for prenatal detection of fetal alpha(0)-thalassemia from maternal plasma. |
| Q90297790 | Development and validation of a haplotype-free technique for non-invasive prenatal diagnosis of spinal muscular atrophy |
| Q36902702 | Development and validation of a measure of informed choice for women undergoing non-invasive prenatal testing for aneuploidy |
| Q90461263 | Development of a comprehensive noninvasive prenatal test |
| Q91846514 | Development of a new methylation-based fetal fraction estimation assay using multiplex ddPCR |
| Q38358449 | Development of new substrates for high-sensitive genotyping of minority mutated alleles |
| Q37479604 | Development of novel noninvasive prenatal testing protocol for whole autosomal recessive disease using picodroplet digital PCR |
| Q38167823 | Diagnosis and prevention of thalassemia |
| Q37722183 | Diagnosis for choroideremia in a large Chinese pedigree by next‑generation sequencing (NGS) and non‑invasive prenatal testing (NIPT). |
| Q38178293 | Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysis |
| Q34132783 | Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study |
| Q34239768 | Differential DNA methylation as a tool for noninvasive prenatal diagnosis (NIPD) of X chromosome aneuploidies |
| Q34575372 | Differentially expressed microRNAs in maternal plasma for the noninvasive prenatal diagnosis of Down syndrome (trisomy 21). |
| Q35916813 | Digital PCR for the molecular detection of fetal chromosomal aneuploidy |
| Q39223783 | Discordant non-invasive prenatal testing (NIPT) - a systematic review. |
| Q93251093 | Discordant sex between fetal screening and postnatal phenotype requires evaluation |
| Q35084533 | Disease specific characteristics of fetal epigenetic markers for non-invasive prenatal testing of trisomy 21 |
| Q38459997 | Disorders of sex development: effect of molecular diagnostics. |
| Q35543094 | Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology |
| Q33561340 | Do miRNAs Play a Role in Fetal Growth Restriction? A Fresh Look to a Busy Corner |
| Q46783562 | Does rat fetal DNA induce preeclampsia in pregnant rats? |
| Q35172041 | Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders |
| Q39060506 | Down syndrome and the complexity of genome dosage imbalance |
| Q40350792 | Droplet digital PCR combined with minisequencing, a new approach to analyze fetal DNA from maternal blood: application to the non-invasive prenatal diagnosis of achondroplasia |
| Q36803713 | Early noninvasive prenatal detection of a fetal CRB1 mutation causing Leber congenital amaurosis. |
| Q36538133 | Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study |
| Q34769596 | Effective noninvasive zygosity determination by maternal plasma target region sequencing |
| Q52913228 | Effective use of the TSPY gene-specific copy number in determining fetal DNA in the maternal blood of cynomolgus monkeys. |
| Q60044678 | Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women |
| Q51071676 | Effectiveness of strict anti-contamination criteria for non-invasive foetal sex determination in a clinical setting. |
| Q40950309 | Effects of Maternal and Fetal Characteristics on Cell-Free Fetal DNA Fraction in Maternal Plasma |
| Q36384651 | Effects of sample processing and storage on the integrity of cell-free miRNAs in maternal plasma |
| Q34224506 | Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury |
| Q46320319 | Elevated plasma levels of hypermethylated RASSF1A gene sequences in pregnant women with intrahepatic cholestasis |
| Q37401069 | Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment |
| Q89967669 | Embryo Biopsy Can Offer More Information Than Just Ploidy Status |
| Q35846774 | Embryonic-maternal cross-talk via exosomes: potential implications |
| Q90689839 | Enrichment of fetal and maternal long cell-free DNA fragments from maternal plasma following DNA repair |
| Q59792872 | Enrichment of the fetal fraction in non-invasive prenatal screening reduces maternal background interference |
| Q61799424 | Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy |
| Q34558118 | Epigenetic approaches for the detection of fetal DNA in maternal plasma |
| Q33797671 | Epigenetic-genetic chromosome dosage approach for fetal trisomy 21 detection using an autosomal genetic reference marker |
| Q58106704 | Ethical Concerns in the Implementation of DNA Sequencing-Based Noninvasive Prenatal Testing for Fetal Aneuploidy Among Obstetric Professionals in Hong Kong |
| Q96137182 | Ethical considerations of gene editing and genetic selection |
| Q92028423 | Evaluation and statistical optimization of a method for methylated cell-free fetal DNA extraction from maternal plasma |
| Q98475414 | Evaluation of Beta -Thalassemia in the Fetus through cffDNA with Multiple Polymorphisms as a Haplotype in the Beta-Globin Gene |
| Q35789626 | Evaluation of a Modified DNA Extraction Method for Isolation of Cell-Free Fetal DNA from Maternal Serum |
| Q34425220 | Evaluation of a novel assay for detection of the fetal marker RASSF1A: facilitating improved diagnostic reliability of noninvasive prenatal diagnosis |
| Q56836330 | Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy |
| Q73714734 | Evaluation of bidirectional transfer of plasma DNA through placenta |
| Q34480344 | Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol |
| Q54566658 | Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. |
| Q45984957 | Evaluation of single-nucleotide polymorphisms as internal controls in prenatal diagnosis of fetal blood groups. |
| Q38452230 | Evaluation of the clinical usefulness of isolation of fetal DNA from the maternal circulation |
| Q45246040 | Evaluation of the impact of density gradient centrifugation on fetal cell loss during enrichment from maternal peripheral blood |
| Q34217503 | Evaluation of two DNA extraction methods from maternal plasma for using in non-invasive bovine fetus gender determination. |
| Q36692481 | Evidence for a role for the adaptive immune response in human term parturition |
| Q35667111 | Exome Sequencing in Fetuses with Structural Malformations |
| Q92756215 | Exosomes-Associated DNA-New Marker in Pregnancy Complications? |
| Q42359656 | Expanded conventional first trimester screening. |
| Q35900347 | Expanding diagnostic testing beyond cytogenetics: implications for birth defects research and surveillance |
| Q88804168 | Extracellular RNA profiles with human age |
| Q37690852 | Extracellular chromosome 21-derived microRNAs in euploid & aneuploid pregnancies |
| Q27012889 | Extracellular nucleic acids in maternal circulation as potential biomarkers for placental insufficiency |
| Q91695814 | Factors affecting cell-free DNA fetal fraction: statistical analysis of 13,661 maternal plasmas for non-invasive prenatal screening |
| Q90467894 | Fast Temperature-Gradient COLD PCR for the enrichment of the paternally inherited SNPs in cell free fetal DNA; an application to non-invasive prenatal diagnosis of β-thalassaemia |
| Q42877106 | Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma--next step toward reliable non-invasive prenatal diagnostics |
| Q46724061 | Feasibility of using plasma rather than serum in first and second trimester multiple marker Down's syndrome screening |
| Q56836344 | Fetal DNA detection in maternal plasma throughout gestation |
| Q38257762 | Fetal DNA in maternal plasma in preeclamptic pregnancies |
| Q38002921 | Fetal DNA in maternal plasma: a noninvasive tool for prenatal diagnosis of beta-thalassemia. |
| Q34333910 | Fetal DNA in maternal plasma: application to non-invasive blood group genotyping of the fetus |
| Q36654711 | Fetal DNA in maternal plasma: progress through epigenetics |
| Q34385179 | Fetal DNA in maternal plasma: the plot thickens and the placental barrier thins |
| Q35990077 | Fetal Genotyping in Maternal Blood by Digital PCR: Towards NIPD of Monogenic Disorders Independently of Parental Origin |
| Q59001540 | Fetal Nucleic Acids in Maternal Circulation: A Genetic Resource for Noninvasive Prenatal Diagnosis |
| Q36837125 | Fetal RHD Genotyping Using Real-Time Polymerase Chain Reaction Analysis of Cell-Free Fetal DNA in Pregnancy of RhD Negative Women in South of Iran. |
| Q50246909 | Fetal RHD Genotyping from Circulating Cell-Free Fetal DNA in Plasma of Rh Negative Pregnant Women in Iran |
| Q46444885 | Fetal RHD genotyping by PCR using plasma from D negative pregnant women |
| Q54393922 | Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation. |
| Q33780684 | Fetal RhD genotyping from maternal plasma |
| Q36571410 | Fetal Sex Determination using Non-Invasive Method of Cell-free Fetal DNA in Maternal Plasma of Pregnant Women During 6(th)- 10(th) Weeks of Gestation |
| Q35976544 | Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn |
| Q36861150 | Fetal blood group genotyping. |
| Q38200256 | Fetal blood grouping using cell free DNA - an improved service for RhD negative pregnant women |
| Q64247657 | Fetal cardiac examination can affect patients' preference on invasive tests: A new data on maternal anxiety indicated karyotyping |
| Q34134209 | Fetal gender and several cytokines are associated with the number of fetal cells in maternal blood--an observational study |
| Q59071813 | Fetal genes in mother's blood |
| Q51889079 | Fetal microchimerism: the cellular and immunological legacy of pregnancy. |
| Q37948857 | Fetal nucleic acids in maternal blood: the promises |
| Q34168875 | Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. |
| Q38868916 | Fetal-specific hypermethylated RASSF1A quantification in pregnancy. |
| Q47960026 | FetalQuant: deducing fractional fetal DNA concentration from massively parallel sequencing of DNA in maternal plasma |
| Q47093534 | FetalQuantSD: accurate quantification of fetal DNA fraction by shallow-depth sequencing of maternal plasma DNA. |
| Q64102119 | Feto-Maternal Microchimerism: The Pre-eclampsia Conundrum |
| Q33897051 | Fetomaternal cell trafficking: a new cause of disease? |
| Q39024055 | Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. |
| Q39084118 | First trimester noninvasive fetal RHD genotyping using maternal dried blood spots |
| Q33769015 | First trimester prenatal diagnosis: fetal cells in the maternal circulation |
| Q38210332 | First trimester screening can predict adverse pregnancy outcomes |
| Q36275303 | First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR |
| Q34702612 | First trimester screening of circulating C19MC microRNAs can predict subsequent onset of gestational hypertension |
| Q77359516 | First-trimester fetal sex determination in maternal serum using real-time PCR |
| Q72989795 | First-trimester fetal sex prediction by deoxyribonucleic acid analysis of maternal peripheral blood |
| Q45875805 | Foetal sex determination in maternal blood from the seventh week of gestation and its role in diagnosing haemophilia in the foetuses of female carriers |
| Q51070173 | Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences. |
| Q43688745 | Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study |
| Q26863327 | Free DNA--new potential analyte in clinical laboratory diagnostics? |
| Q37956500 | From karyotyping to array-CGH in prenatal diagnosis |
| Q34286705 | From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges |
| Q38744479 | Future Science Prize goes to non-invasive prenatal testing |
| Q47623923 | Genetic Counseling for Couples Seeking Noninvasive Prenatal Testing in Japan: Experiences of Pregnant Women and their Partners |
| Q90334337 | Genetic counseling for cystic fibrosis: A basic model with new challenges |
| Q43570601 | Genetic counselors' experience with cell-free fetal DNA testing as a prenatal screening option for aneuploidy |
| Q34501764 | Genetic effects of a 13q31.1 microdeletion detected by noninvasive prenatal testing (NIPT) |
| Q37509474 | Genetics of congenital adrenal hyperplasia |
| Q38562550 | Genome-Wide Sequencing for Prenatal Detection of Fetal Single-Gene Disorders |
| Q51097274 | Genome-wide normalized score: a novel algorithm to detect fetal trisomy 21 during non-invasive prenatal testing. |
| Q92555522 | Genomic Medicine-Progress, Pitfalls, and Promise |
| Q86944820 | Genomic imbalances in circulating DNA in Hodgkin's lymphoma |
| Q38114005 | Genomic medicine: a decade of successes, challenges, and opportunities |
| Q34023027 | Genomic targets in saliva |
| Q24186694 | Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women |
| Q47618331 | Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. |
| Q36946818 | Genotyping analysis of circulating fetal cells reveals high frequency of vanishing twin following transfer of multiple embryos |
| Q31920253 | Genotyping fetal DNA by non-invasive means: extraction from maternal plasma |
| Q42771985 | Getting to know the fetal genome non-invasively: now a reality |
| Q91925385 | Giants in Obstetrics and Gynecology Series: a profile of Christopher Redman, MB, BChir, MRCP, FRCP |
| Q41475376 | Haplotype-based approach for noninvasive prenatal tests of Duchenne muscular dystrophy using cell-free fetal DNA in maternal plasma. |
| Q89982360 | Harmonizing cell-free DNA Collection and Processing Practices through Evidence-based Guidance |
| Q52725964 | Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening. |
| Q54878596 | Healthy children without fear: Reproductive options for patients or couples carrying inherited diseases. |
| Q43889481 | High prevalence of microchimerism in female patients |
| Q62607290 | High prevalence of the His63Asp HFE mutation in italian patients with porphyria cutanea tarda |
| Q89948144 | High-resolution profiling of human cytomegalovirus cell-free DNA in human plasma highlights its exceptionally fragmented nature |
| Q58008242 | High-sensitive microarray substrates specifically designed to improve sensitivity for the identification of fetal paternally inherited sequences in maternal plasma |
| Q28251729 | High-throughput droplet digital PCR system for absolute quantitation of DNA copy number |
| Q34618332 | High-throughput massively parallel sequencing for fetal aneuploidy detection from maternal plasma |
| Q43494882 | How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care |
| Q38236392 | Hyperhomocysteinemia: related genetic diseases and congenital defects, abnormal DNA methylation and newborn screening issues |
| Q33275493 | Hypermethylation of RASSF1A in human and rhesus placentas |
| Q40207944 | Hypoxia-induced membrane-bound apoptotic DNA particles: potential mechanism of fetal DNA in maternal plasma |
| Q37340438 | IONA test for first-trimester detection of trisomies 21, 18 and 13. |
| Q92406714 | Identification and characterization of extrachromosomal circular DNA in maternal plasma |
| Q44069427 | Identification and management of women with inherited bleeding disorders: a survey of obstetricians and gynaecologists in the United Kingdom |
| Q91386709 | Identification of 12 cancer types through genome deep learning |
| Q91069740 | Identification of a de novo fetal variant in osteogenesis imperfecta by targeted sequencing-based noninvasive prenatal testing |
| Q45859656 | Identification of fetal gender in maternal blood is a helpful tool in the prenatal diagnosis of haemophilia. |
| Q37727372 | Identification of messenger RNA of fetoplacental source in maternal plasma of women with normal pregnancies and pregnancies with intrauterine growth restriction |
| Q36770646 | Identification of tissue-specific cell death using methylation patterns of circulating DNA |
| Q27003962 | Identification of trisomy 18, trisomy 13, and Down syndrome from maternal plasma |
| Q26784480 | Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics |
| Q35829427 | Impact of DNA methylation on trophoblast function. |
| Q89635382 | Implementation challenges for an ethical introduction of noninvasive prenatal testing: a qualitative study of healthcare professionals' views from Lebanon and Quebec |
| Q91779483 | Implementation of cell-free DNA-based non-invasive prenatal testing in a National Health Service Regional Genetics Laboratory |
| Q38262952 | Implementation of whole genome massively parallel sequencing for noninvasive prenatal testing in laboratories |
| Q51381812 | Implementing Non-Invasive Prenatal Diagnosis (NIPD) in a National Health Service Laboratory; From Dominant to Recessive Disorders. |
| Q35674630 | Implementing non-invasive RHD genotyping on cell-free foetal DNA from maternal plasma: the Pavia experience |
| Q57839586 | Implementing noninvasive prenatal fetal sex determination using cell-free fetal DNA in the United Kingdom |
| Q28744238 | Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield |
| Q47579497 | Implications of failure to achieve a result from prenatal maternal serum cell-free DNA testing: a historical cohort study |
| Q38655473 | Imprinted NanoVelcro Microchips for Isolation and Characterization of Circulating Fetal Trophoblasts: Toward Noninvasive Prenatal Diagnostics. |
| Q39545562 | Improved detection of Dirofilaria repens DNA by direct polymerase chain reaction |
| Q91162956 | Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA |
| Q60046618 | Improving the calling of non-invasive prenatal testing on 13-/18-/21-trisomy by support vector machine discrimination |
| Q60044395 | Improving women's knowledge about prenatal screening in the era of non-invasive prenatal testing for Down syndrome - development and acceptability of a low literacy decision aid |
| Q37986405 | In utero intervention for urologic diseases |
| Q54319440 | Increased Y-chromosome detection by SRY duplexing. |
| Q36354286 | Increased death of adipose cells, a path to release cell-free DNA into systemic circulation of obese women |
| Q91591027 | Inflammation-mediated generation and inflammatory potential of human placental cell-free fetal DNA |
| Q35035846 | Influence of plasma processing on recovery and analysis of circulating nucleic acids |
| Q53191016 | Influence of temperature during transportation on cell-free DNA analysis. |
| Q34318906 | Informatics-based, highly accurate, noninvasive prenatal paternity testing |
| Q47366013 | Informative priors on fetal fraction increase power of the noninvasive prenatal screen |
| Q34259111 | Insights into fetal and neonatal development through analysis of cell-free RNA in body fluids |
| Q36787475 | Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road? |
| Q38178923 | Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care |
| Q34568851 | Inter-individual methylation variability in differentially methylated regions between maternal whole blood and first trimester CVS. |
| Q40759826 | Intrauterine death in singleton pregnancies with trisomy 21, 18, 13 and monosomy X. |
| Q38211988 | Introducing WISECONDOR for noninvasive prenatal diagnostics |
| Q35611090 | Invasive & non-invasive approaches for prenatal diagnosis of haemoglobinopathies: experiences from India |
| Q37529449 | Investigating and correcting plasma DNA sequencing coverage bias to enhance aneuploidy discovery |
| Q47586484 | Isolation and whole genome sequencing of fetal cells from maternal blood towards the ultimate non-invasive prenatal testing |
| Q34338007 | Isolation of fetal cells from the maternal circulation: prospects for the non-invasive prenatal diagnosis |
| Q33187659 | Isolation of fetal nucleated red blood cells from maternal blood |
| Q64089321 | Journal of Translational Medicine advances in Translational Genomics and Genetics Era |
| Q52571170 | Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. |
| Q34107990 | Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis |
| Q33634135 | Knowledge and Attitudes Regarding Non-Invasive Prenatal Testing (NIPT) and Preferences for Risk Information among High School Students in Sweden |
| Q39021174 | Knowledge, understanding, and uptake of noninvasive prenatal testing among Latina women |
| Q38181003 | Lab-on-a-chip technology: impacting non-invasive prenatal diagnostics (NIPD) through miniaturisation |
| Q78296531 | Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis |
| Q50792929 | Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. |
| Q37628173 | Liquid Biopsies for Cancer: Coming to a Patient near You. |
| Q39149201 | Liquid biopsies come of age: towards implementation of circulating tumour DNA. |
| Q27010159 | Liquid biopsies: genotyping circulating tumor DNA |
| Q35045583 | Long-term persistence and effects of fetal microchimerisms on disease onset and status in a cohort of women with rheumatoid arthritis and systemic lupus erythematosus |
| Q35219358 | Longitudinal expression of Toll-like receptors on dendritic cells in uncomplicated pregnancy and postpartum |
| Q39278884 | Lost in Translation? Ethical Challenges of Implementing a New Diagnostic Procedure |
| Q36270673 | Luteal phase serum cell-free DNA as a marker of failed pregnancy after assisted reproductive technology |
| Q33737845 | MALDI-TOF MS in Prenatal Genomics |
| Q33263722 | MALDI-TOF mass spectrometry for quantitative, specific, and sensitive analysis of DNA and RNA. |
| Q36986986 | MS analysis of single-nucleotide differences in circulating nucleic acids: Application to noninvasive prenatal diagnosis. |
| Q38685481 | Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective |
| Q35888435 | Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction |
| Q35099257 | Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids |
| Q50228404 | Maternal 47,XX,i(X)(q10) as a cause of false positive sex chromosome aneuploidy in noninvasive prenatal screening |
| Q56937251 | Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus |
| Q35667145 | Maternal Serum Screening Markers and Adverse Outcome: A New Perspective |
| Q77359744 | Maternal or fetal origin of rhesus monkey (Macaca mulatta) amniotic fluid leukocytes can be identified by polymerase chain reaction using the zinc finger Y gene |
| Q50851221 | Maternal plasma fetal DNA as a marker for preterm labour. |
| Q52632153 | Maternal-fetal cross talk through cell-free fetal DNA, telomere shortening, microchimerism, and inflammation. |
| Q41496938 | MeDIP Real-Time qPCR has the Potential for Noninvasive Prenatal Screening of Fetal Trisomy 21. |
| Q55424345 | MeDIP combined with in-solution targeted enrichment followed by NGS: Inter-individual methylation variability of fetal-specific biomarkers and their implementation in a proof of concept study for NIPT. |
| Q47130174 | Measurement of fetal fraction in cell-free DNA from maternal plasma using a panel of insertion/deletion polymorphisms |
| Q43169721 | Measurement of mRNA of trophoblast-specific genes in cellular and plasma components of maternal blood |
| Q38973677 | Measuring circulating placental RNAs to non-invasively assess the placental transcriptome and to predict pregnancy complications. |
| Q48012169 | Measuring maternal serum screening markers for Down's syndrome in plasma collected for cell-free DNA testing |
| Q47140110 | Medical genetics and genomic medicine in the United States. Part 2: Reproductive genetics, newborn screening, genetic counseling, training, and registries. |
| Q37185416 | Method for extraction of high-quantity and -quality cell-free DNA from amniotic fluid |
| Q38119159 | Micro-scale blood plasma separation: from acoustophoresis to egg-beaters. |
| Q49379649 | MicroRNA expression profiling in placenta and maternal plasma in early pregnancy loss |
| Q28391495 | MicroRNAs: their discovery, biogenesis, function and potential use as biomarkers in non-invasive prenatal diagnostics |
| Q58256594 | Microarray Detection of Fetal DNA Levels in Maternal Plasma |
| Q27025214 | Microarray comparative genomic hybridization in prenatal diagnosis: a review |
| Q35730355 | Microarray-Based Analysis of Methylation Status of CpGs in Placental DNA and Maternal Blood DNA--Potential New Epigenetic Biomarkers for Cell Free Fetal DNA-Based Diagnosis |
| Q34646812 | Microchimerism in autoimmunity and transplantation: potential relevance to multiple sclerosis |
| Q35142853 | Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service |
| Q36272058 | Modified isocratic capillary electrophoresis detection of cell-free DNA in semen |
| Q36247154 | Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies |
| Q38089080 | Molecular diagnostics for haemoglobinopathies |
| Q33414351 | Molecular typing of human platelet and neutrophil antigens (HPA and HNA). |
| Q35060714 | Motivations for undertaking DNA sequencing-based non-invasive prenatal testing for fetal aneuploidy: a qualitative study with early adopter patients in Hong Kong |
| Q36057226 | Multiplex PCR for 17 Y-chromosome Specific Short Tandem Repeats (STR) to enhance the reliability of fetal sex determination in maternal plasma |
| Q35977714 | NIPT and Informed Consent: an Assessment of Patient Understanding of a Negative NIPT Result |
| Q39213958 | NIPT: current utilization and implications for the future of prenatal genetic counseling. |
| Q33921152 | Naturally acquired microchimerism |
| Q33755108 | New aids for the non-invasive prenatal diagnosis of achondroplasia: dysmorphic features, charts of fetal size and molecular confirmation using cell-free fetal DNA in maternal plasma. |
| Q36874235 | New technologies in immunohaematology |
| Q37316945 | Next generation sequencing of SNPs for non-invasive prenatal diagnosis: challenges and feasibility as illustrated by an application to β-thalassaemia. |
| Q44639381 | Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma |
| Q37181536 | Non invasive prenatal diagnosis of aneuploidy: next generation sequencing or fetal DNA enrichment? |
| Q26827338 | Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects |
| Q36335133 | Non-Invasive Screening Tools for Down's Syndrome: A Review |
| Q38088834 | Non-coding RNA and DNA as epigenetic biomarkers for pre-eclampsia |
| Q85181748 | Non-invasive Prenatal Diagnosis |
| Q38984776 | Non-invasive Prenatal Diagnosis for BRCA Mutations - a Qualitative Pilot Study of Health Professionals' Views |
| Q51418234 | Non-invasive Prenatal Diagnosis of Chromosomal Aneuploidies and Microdeletion Syndrome Using Fetal Nucleated Red Blood Cells Isolated by Nanostructure Microchips. |
| Q36847554 | Non-invasive Prenatal Testing: Technologies, Clinical Assays and Implementation Strategies for Women's Healthcare Practitioners |
| Q34149751 | Non-invasive aneuploidy detection using free fetal DNA and RNA in maternal plasma: recent progress and future possibilities |
| Q36431820 | Non-invasive antenatal RHD typing |
| Q77961995 | Non-invasive determination of the paternal HLA haplotype of a fetus using kinetic PCR to detect fetal microchimerism in maternal plasma |
| Q45891469 | Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges. |
| Q54677055 | Non-invasive fetal RHD and RHCE genotyping using real-time PCR testing of maternal plasma in RhD-negative pregnancies. |
| Q50762528 | Non-invasive fetal RHD exon 7 and exon 10 genotyping using real-time PCR testing of fetal DNA in maternal plasma. |
| Q56001887 | Non-invasive fetal RHD genotyping in the first trimester of pregnancy |
| Q44377059 | Non-invasive fetal sex determination by maternal plasma sequencing and application in X-linked disorder counseling |
| Q54764349 | Non-invasive fetal sex determination using a conventional nested PCR analysis of fetal DNA in maternal plasma. |
| Q51172911 | Non-invasive fetal sex determination using real-time PCR. |
| Q55418615 | Non-invasive fetal sex diagnosis in plasma of early weeks pregnants using droplet digital PCR. |
| Q45855202 | Non-invasive first trimester determination of fetal gender: a new approach for prenatal diagnosis of haemophilia |
| Q43056215 | Non-invasive foetal RHD genotyping in transfusion medicine |
| Q34482155 | Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study |
| Q34688588 | Non-invasive prenatal detection of achondroplasia using circulating fetal DNA in maternal plasma |
| Q44982893 | Non-invasive prenatal determination of fetal sex: translating research into clinical practice |
| Q37809306 | Non-invasive prenatal diagnosis by fetal nucleic acid analysis in maternal plasma: the coming of age |
| Q36079264 | Non-invasive prenatal diagnosis by massively parallel sequencing of maternal plasma DNA. |
| Q46118085 | Non-invasive prenatal diagnosis from the perspective of a low-resource country |
| Q36895493 | Non-invasive prenatal diagnosis of Duchenne and Becker muscular dystrophies by relative haplotype dosage |
| Q36311237 | Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach. |
| Q36424760 | Non-invasive prenatal diagnosis of aneuploidies: new technologies and clinical applications |
| Q54313935 | Non-invasive prenatal diagnosis of beta-thalassemia and sickle-cell disease using pyrophosphorolysis-activated polymerization and melting curve analysis. |
| Q48150902 | Non-invasive prenatal diagnosis of beta-thalassemia by semiconductor sequencing: a feasibility study in the sardinian population. |
| Q79756522 | Non-invasive prenatal diagnosis of fetal aneuploidies |
| Q57079533 | Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells |
| Q26823325 | Non-invasive prenatal diagnosis of fetal trisomy 21 using cell-free fetal DNA in maternal blood |
| Q50631143 | Non-invasive prenatal diagnosis of monogenic disorders: an optimized protocol using MEMO qPCR with miniSTR as internal control. |
| Q34510647 | Non-invasive prenatal diagnosis of multiple endocrine neoplasia type 2A using COLD-PCR combined with HRM genotyping analysis from maternal serum |
| Q37745036 | Non-invasive prenatal diagnosis of spinal muscular atrophy by relative haplotype dosage |
| Q38770436 | Non-invasive prenatal diagnosis of β-thalassemia by detection of the cell-free fetal DNA in maternal circulation: a systematic review and meta-analysis. |
| Q36117921 | Non-invasive prenatal diagnosis using cell-free fetal nucleic acids in maternal plasma: Progress overview beyond predictive and personalized diagnosis |
| Q35885009 | Non-invasive prenatal diagnosis using fetal DNA in maternal plasma: a preliminary study for identification of paternally-inherited alleles using single nucleotide polymorphisms |
| Q35073312 | Non-invasive prenatal diagnosis: on the horizon? |
| Q38208530 | Non-invasive prenatal diagnosis: progress and potential |
| Q34399889 | Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-analysis |
| Q38088416 | Non-invasive prenatal diagnostics using next generation sequencing: technical, legal and social challenges |
| Q54510423 | Non-invasive prenatal paternity testing from maternal blood. |
| Q90396106 | Non-invasive prenatal rhesus D genotyping using cell-free foetal DNA |
| Q38838610 | Non-invasive prenatal screening versus prenatal diagnosis by array comparative genomic hybridization: a comparative retrospective study. |
| Q91259903 | Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA |
| Q48100099 | Non-invasive prenatal testing (NIPT): Europe's first multicenter post-market clinical follow-up study validating the quality in clinical routine. |
| Q36184534 | Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening |
| Q38565317 | Non-invasive prenatal testing for aneuploidy: a systematic review of Internet advertising to potential users by commercial companies and private health providers |
| Q38114375 | Non-invasive prenatal testing for aneuploidy: current status and future prospects |
| Q27007785 | Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center |
| Q26764809 | Non-invasive prenatal testing for fetal chromosome abnormalities: review of clinical and ethical issues |
| Q50051267 | Non-invasive prenatal testing for fetal inheritance of maternal β-thalassaemia mutations using targeted sequencing and relative mutation dosage: a feasibility study |
| Q101049747 | Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation |
| Q46816545 | Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing |
| Q93108658 | Non-invasive prenatal testing reveals copy number variations related to pregnancy complications |
| Q64969403 | Non-invasive prenatal testing to detect chromosome aneuploidies in 57,204 pregnancies. |
| Q39113200 | Non-invasive prenatal testing: UK genetic counselors' experiences and perspectives |
| Q26999426 | Non-invasive prenatal testing: a review of international implementation and challenges |
| Q34328617 | Non-invasive prenatal testing: ethical issues explored |
| Q51074981 | Non-invasive prenatal testing: ethics and policy considerations. |
| Q45869375 | Non-invasive tool for foetal sex determination in early gestational age. |
| Q37809342 | Noninvasive Approaches to Prenatal Diagnosis of Hemoglobinopathies Using Fetal DNA in Maternal Plasma |
| Q35602040 | Noninvasive Digital Detection of Fetal DNA in Plasma of 4-Week-Pregnant Women following In Vitro Fertilization and Embryo Transfer |
| Q34496747 | Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies |
| Q90358117 | Noninvasive Prenatal Diagnostics: Recent Developments Using Circulating Fetal Nucleated Cells |
| Q36133962 | Noninvasive Prenatal Paternity Testing (NIPAT) through Maternal Plasma DNA Sequencing: A Pilot Study |
| Q38549770 | Noninvasive Prenatal Screening for Genetic Diseases Using Massively Parallel Sequencing of Maternal Plasma DNA |
| Q55438251 | Noninvasive Prenatal Testing: Comparison of Two Mappers and Influence in the Diagnostic Yield. |
| Q58308698 | Noninvasive Prenatal Testing: Implications for Muslim Communities |
| Q37810121 | Noninvasive approach for the management of hemolytic disease of the fetus |
| Q34382581 | Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing |
| Q22242878 | Noninvasive detection of fetal trisomy 21: systematic review and report of quality and outcomes of diagnostic accuracy studies performed between 1997 and 2012 |
| Q54646324 | Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma. |
| Q24657306 | Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood |
| Q87466211 | Noninvasive fetal RhD genotyping |
| Q34192088 | Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience |
| Q37056703 | Noninvasive fetal genome sequencing: a primer |
| Q33396206 | Noninvasive fetal genotyping of human platelet antigen-1a |
| Q33421975 | Noninvasive fetal genotyping of human platelet antigen-1a using targeted massively parallel sequencing |
| Q51368842 | Noninvasive fetal sex determination in maternal plasma: a prospective feasibility study. |
| Q34028063 | Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis |
| Q47729283 | Noninvasive fetal trisomy 21 detection using chromosome-selective sequencing: a variation of the molecular counting theme |
| Q34807426 | Noninvasive prenatal detection for pathogenic CNVs: the application in α-thalassemia |
| Q46170290 | Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma |
| Q26783426 | Noninvasive prenatal diagnosis |
| Q89556540 | Noninvasive prenatal diagnosis by genome-wide haplotyping of cell-free plasma DNA |
| Q37998943 | Noninvasive prenatal diagnosis empowered by high-throughput sequencing |
| Q44912114 | Noninvasive prenatal diagnosis experience in the Çukurova Region of Southern Turkey: detecting paternal mutations of sickle cell anemia and β-thalassemia in cell-free fetal DNA using high-resolution melting analysis |
| Q50755226 | Noninvasive prenatal diagnosis for hemoglobin Bart's hydrops fetalis. |
| Q41287608 | Noninvasive prenatal diagnosis of 21-Hydroxylase deficiency using target capture sequencing of maternal plasma DNA. |
| Q36225300 | Noninvasive prenatal diagnosis of Down syndrome in samples from Southwest Chinese gravidas using pregnant plasma placental RNA allelic ratio |
| Q39029759 | Noninvasive prenatal diagnosis of Huntington disease: detection of the paternally inherited expanded CAG repeat in maternal plasma |
| Q37592253 | Noninvasive prenatal diagnosis of fetal aneuploidies and Mendelian disorders: new innovative strategies |
| Q37010246 | Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma |
| Q28742844 | Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing |
| Q28729130 | Noninvasive prenatal diagnosis of fetal trisomy 21 by allelic ratio analysis using targeted massively parallel sequencing of maternal plasma DNA |
| Q37000915 | Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma |
| Q38002933 | Noninvasive prenatal diagnosis of monogenic disorders |
| Q90366836 | Noninvasive prenatal diagnosis of β-thalassemia by relative haplotype dosage without analyzing proband |
| Q37705437 | Noninvasive prenatal diagnosis using ccffDNA in maternal blood: state of the art. |
| Q35577099 | Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake |
| Q34683906 | Noninvasive prenatal molecular karyotyping from maternal plasma |
| Q91580650 | Noninvasive prenatal paternity testing by maternal plasma DNA sequencing in twin pregnancies |
| Q34535626 | Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics |
| Q102379514 | Noninvasive prenatal test of single-gene disorders by linked-read direct haplotyping: application in various diseases |
| Q52837725 | Noninvasive prenatal testing and fetal sonographic screening: roundtable discussion. |
| Q39149988 | Noninvasive prenatal testing by maternal plasma DNA analysis: current practice and future applications |
| Q47101455 | Noninvasive prenatal testing complicated by maternal malignancy: new tools for a complex problem |
| Q39004076 | Noninvasive prenatal testing for aneuploidy using cell-free DNA - New implications for maternal health. |
| Q35168913 | Noninvasive prenatal testing for autosomal recessive conditions by maternal plasma sequencing in a case of congenital deafness |
| Q64103083 | Noninvasive prenatal testing for chromosome aneuploidies and subchromosomal microdeletions/microduplications in a cohort of 8141 single pregnancies |
| Q64945044 | Noninvasive prenatal testing for fetal subchromosomal copy number variations and chromosomal aneuploidy by low-pass whole-genome sequencing. |
| Q38125511 | Noninvasive prenatal testing for trisomy 21: challenges for implementation in Australia |
| Q34426439 | Noninvasive prenatal testing in China: Future detection of rare genetic diseases? |
| Q27324761 | Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management |
| Q35544623 | Noninvasive prenatal testing using cell-free fetal DNA in maternal plasma |
| Q44274066 | Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors |
| Q38182095 | Noninvasive prenatal testing: the future is now. |
| Q48240788 | Noninvasive prenatal testing: the paradigm is shifting rapidly |
| Q36848484 | Noninvasive screening tools for Down syndrome: a review |
| Q33686861 | Novel Algorithms for Improved Sensitivity in Non-Invasive Prenatal Testing |
| Q37866719 | Novel approaches to manipulating foetal cells in the maternal circulation for non-invasive prenatal diagnosis of the unborn child |
| Q43861652 | Nucleic acid-based non-invasive prenatal diagnosis of genetic skin diseases: are we ready? |
| Q41611034 | Obstetric professionals' perceptions of non-invasive prenatal testing for Down syndrome: clinical usefulness compared with existing tests and ethical implications. |
| Q35845489 | Old Questions, New Paradigms: Ethical, Legal, and Social Complications of Noninvasive Prenatal Testing |
| Q50025522 | One-step noninvasive prenatal testing (NIPT) for autosomal recessive homozygous point mutations using digital PCR. |
| Q51407385 | Open source non-invasive prenatal testing platform and its performance in a public health laboratory. |
| Q38659564 | Opening Pandora's box?: ethical issues in prenatal whole genome and exome sequencing |
| Q64077209 | Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin |
| Q50093623 | Origin and clinical relevance of chromosomal aberrations other than the common trisomies detected by genome-wide NIPS: results of the TRIDENT study |
| Q30249103 | Origins, structures, and functions of circulating DNA in oncology |
| Q36335161 | Overview of Five-Years of Experience Performing Non-Invasive Fetal Sex Assessment in Maternal Blood |
| Q38418823 | Overview of the impact of noninvasive prenatal testing on diagnostic procedures |
| Q35049156 | Paternal RHD zygosity determination in Tunisians: evaluation of three molecular tests |
| Q90664762 | Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications |
| Q36077332 | Performance Evaluation of NIPT in Detection of Chromosomal Copy Number Variants Using Low-Coverage Whole-Genome Sequencing of Plasma DNA. |
| Q35839919 | Performance of Droplet Digital PCR in Non-Invasive Fetal RHD Genotyping - Comparison with a Routine Real-Time PCR Based Approach |
| Q36107557 | Performance of Momguard, a new non-invasive prenatal testing protocol developed in Korea |
| Q38669750 | Performance of non-invasive prenatal screening for fetal aneuploidy in twin pregnancies: a meta-analysis |
| Q38819581 | Perinatal Bacterial Exposure Contributes to IL-13 Aeroallergen Response |
| Q64903520 | Perinatal Palliative Care: A qualitative study evaluating the perspectives of pregnancy counselors. |
| Q26852989 | Perinatal systemic gene delivery using adeno-associated viral vectors |
| Q50747962 | Personalized medicine in the care of the child with congenital heart disease: discovery to application. |
| Q64229472 | Pilot study of a novel multi-functional noninvasive prenatal test on fetus aneuploidy, copy number variation, and single-gene disorder screening |
| Q92032662 | Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians |
| Q90600016 | Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers |
| Q33466029 | Placenta-derived fetal specific mRNA is more readily detectable in maternal plasma than in whole blood |
| Q37925148 | Placental immunology and maternal alloimmune responses |
| Q34955670 | Placental mRNA in maternal plasma: prospects for fetal screening |
| Q44702992 | Placental methylation markers in normal and trisomy 21 tissues |
| Q37822751 | Placental microparticles, DNA, and RNA in preeclampsia |
| Q30667824 | Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments |
| Q34428186 | Plasma DNA, prediction and post-traumatic complications |
| Q37943745 | Plasma nucleic acid analysis by massively parallel sequencing: pathological insights and diagnostic implications |
| Q33268343 | Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection |
| Q36022080 | Positive Attitudes towards Non-Invasive Prenatal Testing (NIPT) in a Swedish Cohort of 1,003 Pregnant Women |
| Q36290290 | Postnatal and non-invasive prenatal detection of β-thalassemia mutations based on Taqman genotyping assays |
| Q37278804 | Potential markers of preeclampsia--a review |
| Q89940349 | Potential of Next-Generation Sequencing in Noninvasive Fetal Molecular Blood Group Genotyping |
| Q98289701 | Potential value of circulating tumor DNA in gynecological tumors |
| Q35034936 | Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD |
| Q46302568 | Pre-eclampsia: Molecular events to biomarkers |
| Q54412875 | Prediction of Fetal Sex by Amplification of Fetal DNA Present in Cow Plasma |
| Q64107405 | Preferences for aspects of antenatal and newborn screening: a systematic review |
| Q56001884 | Pregnancy-Associated MicroRNAs in Maternal Plasma: A Channel for Fetal–Maternal Communication? |
| Q73074402 | Prenatal DNA diagnosis of a single-gene disorder from maternal plasma |
| Q34549394 | Prenatal Diagnosis of β-Thalassemias and Hemoglobinopathies |
| Q102331644 | Prenatal RHD genotyping in Croatia: preliminary results |
| Q38954748 | Prenatal and pre-implantation genetic diagnosis |
| Q38791702 | Prenatal cfDNA screening results indicative of maternal neoplasm: survey of current practice and management needs. |
| Q73299262 | Prenatal detection of fetal Down's syndrome from maternal plasma |
| Q73398751 | Prenatal detection of fetal hemoglobin E gene from maternal plasma |
| Q38077524 | Prenatal diagnosis and 47,XXY. |
| Q45871116 | Prenatal diagnosis and preimplantation genetic diagnosis: novel technologies and state of the art of PGD in different regions of the world |
| Q35143173 | Prenatal diagnosis for chromosome abnormalities: past, present and future |
| Q81575251 | Prenatal diagnosis in maternal plasma of a fetal mutation causing propionic acidemia |
| Q44111684 | Prenatal diagnosis of haemophilia B: the Italian experience |
| Q54342215 | Prenatal diagnosis of homozygous alpha-thalassemia-1 by cell-free fetal DNA in maternal plasma. |
| Q34333090 | Prenatal diagnosis using fetal cells and free fetal DNA in maternal blood |
| Q36673937 | Prenatal diagnosis: progress through plasma nucleic acids |
| Q37322448 | Prenatal diagnosis: update on invasive versus noninvasive fetal diagnostic testing from maternal blood |
| Q58029823 | Prenatal exclusion of β thalassaemia major by examination of maternal plasma |
| Q35746622 | Prenatal gender determination and the diagnosis of genital anomalies. |
| Q48487718 | Prenatal genetic care: debates and considerations of the past, present and future |
| Q54741354 | Prenatal genotyping of RHD and SRY using maternal blood. |
| Q73527268 | Prenatal identification of fetal genetic traits |
| Q92041364 | Prenatal maternal biomarkers for the early diagnosis of congenital malformations: A review |
| Q54088983 | Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis. |
| Q36783335 | Prenatal screening methods for aneuploidies |
| Q84836506 | Prenatal testing for Down syndrome: comparison of screening practices in the UK and USA |
| Q33418571 | Prenatal testing for hemolytic disease of the newborn and fetal neonatal alloimmune thrombocytopenia - current status |
| Q38013728 | Prenatal treatment of congenital adrenal hyperplasia-not standard of care |
| Q52895886 | Prenatal two- and three-dimensional imaging in two cases of severe penoscrotal hypospadias. |
| Q74716262 | Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients |
| Q42147598 | Presence of embryonic DNA in culture medium |
| Q35396504 | Presence of mitochondrial tRNA(Leu(UUR)) A to G 3243 mutation in DNA extracted from serum and plasma of patients with type 2 diabetes mellitus. |
| Q35977052 | Prevalence of RhD status and clinical application of non-invasive prenatal determination of fetal RHD in maternal plasma: a 5 year experience in Cyprus |
| Q90902860 | Principles of DNA methylation and their implications for biology and medicine |
| Q73827217 | Probing the fetal genome: progress in non-invasive prenatal diagnosis |
| Q37340939 | Profile of Dennis Lo. |
| Q35919867 | Profiling circulating microRNAs in maternal serum and plasma |
| Q92969803 | Prospective head-to-head comparison of accuracy of two sequencing platforms for screening for fetal aneuploidy by cell-free DNA: the PEGASUS study |
| Q38835303 | Proteomic profile of serum of pregnant women carring a fetus with Down syndrome using nano uplc Q-tof ms/ms technology |
| Q43465721 | Public viewpoints on new non-invasive prenatal genetic tests |
| Q36404290 | Quantification and Application of Potential Epigenetic Markers in Maternal Plasma of Pregnancies with Hypertensive Disorders |
| Q30987480 | Quantification of Fetal DNA by Use of Methylation-Based DNA Discrimination |
| Q74502860 | Quantification of all fetal nucleated cells in maternal blood between the 18th and 22nd weeks of pregnancy using molecular cytogenetic techniques |
| Q33838434 | Quantification of cell-free DNA in normal and complicated pregnancies: overcoming biological and technical issues |
| Q57557766 | Quantification of circulating fetal DNA as a tool for potential monitoring of pregnant patients with antiphospholipid antibodies |
| Q39727263 | Quantification of free fetal DNA in multiple pregnancies and relationship with chorionicity |
| Q36820478 | Quantification of maternal serum cell-free fetal DNA in early-onset preeclampsia |
| Q64121578 | Quantifying circulating cell-free DNA in humans |
| Q32137613 | Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma |
| Q24794995 | Quantitative analysis of DNA levels in maternal plasma in normal and Down syndrome pregnancies |
| Q54274740 | Quantitative analysis of fetal DNA in maternal plasma in gestational diabetes mellitus, iron deficiency anemia and gestational hypertension pregnancies. |
| Q38359104 | Quantitative analysis of male fetal DNA in maternal serum of gravid rhesus monkeys (Macaca mulatta). |
| Q54266875 | RASSF1A in maternal plasma as a molecular marker of preeclampsia. |
| Q39198232 | Raising antibodies against circulating foetal cells from maternal peripheral blood. |
| Q38919733 | Rapid Detection of Cell-Free Mycobacterium tuberculosis DNA in Tuberculous Pleural Effusion |
| Q37181558 | Rapid and non invasive prenatal diagnosis. |
| Q34388637 | Rapid clearance of fetal DNA from maternal plasma |
| Q37560285 | Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods |
| Q33659051 | Rapid prenatal diagnosis of trisomy 21 by real-time quantitative polymerase chain reaction with amplification of small tandem repeats and S100B in chromosome 21 |
| Q26861681 | Recent advances in clinical applications of circulating cell-free DNA integrity |
| Q36063025 | Recent advances in fetal nucleic acids in maternal plasma |
| Q37000825 | Recent advances in non-invasive prenatal DNA diagnosis through analysis of maternal blood. |
| Q28071888 | Recent advances in prenatal genetic screening and testing |
| Q34312211 | Recent advances in the prenatal interrogation of the human fetal genome |
| Q36943811 | Recent advances of genomic testing in perinatal medicine |
| Q33237610 | Recent developments in fetal nucleic acids in maternal plasma: implications to noninvasive prenatal fetal blood group genotyping |
| Q56927575 | Recent developments in genetics and medically assisted reproduction: from research to clinical applications |
| Q93118941 | Recent developments in genetics and medically-assisted reproduction: from research to clinical applications†‡ |
| Q38594354 | Recent patents and technology transfer for molecular diagnosis of β-thalassemia and other hemoglobinopathies |
| Q33425658 | Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. |
| Q64983063 | Recent trends in prenatal genetic screening and testing. |
| Q22241774 | Red cell genotyping and the future of pretransfusion testing |
| Q44967041 | Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro |
| Q36794228 | Reliable Determination of Fetal RhD Status by RHD Genotyping from Maternal Plasma |
| Q34042854 | Reliable detection of paternal SNPs within deletion breakpoints for non-invasive prenatal exclusion of homozygous α-thalassemia in maternal plasma |
| Q34769683 | Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing |
| Q46172895 | Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis |
| Q26991553 | Review: cell-free fetal DNA in the maternal circulation as an indication of placental health and disease |
| Q38085053 | Role of IgG antibodies in association with placental function and immunologic diseases in human pregnancy |
| Q38179321 | Role of the second-trimester 'genetic sonogram' for Down syndrome screen in the era of first-trimester screening and noninvasive prenatal testing |
| Q27687533 | Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice |
| Q51899817 | Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. |
| Q46227317 | Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark. |
| Q34853996 | Routine testing of fetal Rhesus D status in Rhesus D negative women using cell-free fetal DNA: an investigation into the preferences and information needs of women |
| Q24627800 | SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy |
| Q36064190 | SRY sequence in maternal plasma: Implications for non-invasive prenatal diagnosis: First report from India |
| Q33404325 | Safe fetal platelet genotyping: new developments |
| Q34200702 | Safe, accurate, prenatal diagnosis of thanatophoric dysplasia using ultrasound and free fetal DNA. |
| Q50058086 | Screening for fetal chromosomal and subchromosomal disorders |
| Q47641657 | Screening for trisomies 21 and 18 in a Spanish public hospital: from the combined test to the cell-free DNA test |
| Q34308038 | Screening significantly hypermethylated genes in fetal tissues compared with maternal blood using a methylated-CpG island recovery assay-based microarray |
| Q37514951 | Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends. |
| Q36954067 | Second-generation non-invasive high-throughput DNA sequencing technology in the screening of Down's syndrome in advanced maternal age women |
| Q50456746 | Secrets of life in a spoonful of blood. |
| Q92239589 | Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects |
| Q47900162 | Sensitive Monogenic Noninvasive Prenatal Diagnosis by Targeted Haplotyping |
| Q37397918 | Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands |
| Q92512130 | Sequencing of short cfDNA fragments in NIPT improves fetal fraction with higher maternal BMI and early gestational age |
| Q48333204 | Serum levels of genomic DNA of α1(I) collagen are elevated in scleroderma patients. |
| Q58706796 | Service provision of non-invasive prenatal testing for Down syndrome in public and private healthcare sectors: a qualitative study with obstetric providers |
| Q52714951 | Simultaneous Discovery of Cell-Free DNA and the Nucleosome Ladder. |
| Q34088575 | Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort |
| Q37164146 | Sites of differential DNA methylation between placenta and peripheral blood: molecular markers for noninvasive prenatal diagnosis of aneuploidies |
| Q34295095 | Six consecutive false positive cases from cell-free fetal DNA testing in a single referring centre |
| Q92063441 | Size profile of cell-free DNA: A beacon guiding the practice and innovation of clinical testing |
| Q33767643 | Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. |
| Q37593355 | Size-selective separation and overall-amplification of cell-free fetal DNA fragments using PCR-based enrichment. |
| Q55209454 | Size-tagged preferred ends in maternal plasma DNA shed light on the production mechanism and show utility in noninvasive prenatal testing. |
| Q50912004 | Specific real-time PCR vs. fluorescent dyes for serum free DNA quantification. |
| Q38563344 | Stability of cell-free DNA from maternal plasma isolated following a single centrifugation step |
| Q36245906 | Statistical Approach to Decreasing the Error Rate of Noninvasive Prenatal Aneuploid Detection caused by Maternal Copy Number Variation |
| Q38633211 | Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals |
| Q34388262 | Strategies for rare-event detection: an approach for automated fetal cell detection in maternal blood |
| Q92558230 | Successful early fetal sex determination using cell-free fetal DNA isolated from maternal capillary blood: A pilot study |
| Q33770229 | Systematic identification of placental epigenetic signatures for the noninvasive prenatal detection of Edwards syndrome |
| Q38656110 | Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland |
| Q91936492 | Targeted capture enrichment followed by NGS: development and validation of a single comprehensive NIPT for chromosomal aneuploidies, microdeletion syndromes and monogenic diseases |
| Q91875022 | Targeted fetal cell-free DNA screening for aneuploidies in 4,594 pregnancies: Single center study |
| Q55209536 | Targeted linked-read sequencing for direct haplotype phasing of maternal DMD alleles: a practical and reliable method for noninvasive prenatal diagnosis. |
| Q34936608 | Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program |
| Q28287812 | Telegony, the sire effect and non-mendelian inheritance mediated by spermatozoa: a historical overview and modern mechanistic speculations |
| Q57006303 | Testing normality of fetal DNA concentration in maternal plasma at 10-12 completed weeks' gestation: a preliminary approach to a new marker for genetic screening |
| Q90372343 | The 100 most-cited articles on prenatal diagnosis: A bibliometric analysis |
| Q89467803 | The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB |
| Q92538569 | The Cellular Transcriptome in the Maternal Circulation During Normal Pregnancy: A Longitudinal Study |
| Q53596947 | The Diagnosis Pattern of Mid-Trimester Fetal Chromosomal Aneuploidy in Xuzhou and the Clinical Applications. |
| Q64066279 | The Effect of Freezing on Non-invasive Prenatal Testing |
| Q33891689 | The Epigenome View: An Effort towards Non-Invasive Prenatal Diagnosis |
| Q36423155 | The Glass Slide Extraction System Snap Card Improves Non-Invasive Prenatal Genotyping in Pregnancies with Antibodies |
| Q87298407 | The Integration of Noninvasive Prenatal Screening into the Existing Prenatal Paradigm: a Survey of Current Genetic Counseling Practice |
| Q55007705 | The Most Favourable Procedure for the Isolation of Cell-Free DNA from the Plasma of Iso-Immunized RHD-Negative Pregnant Women. |
| Q85023769 | The Quest for Accurate Measurement of Fetal DNA in Maternal Plasma |
| Q58788640 | The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy |
| Q30250029 | The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. |
| Q59795817 | The application of NIPT using combinatorial probe-anchor synthesis to identify sex chromosomal aneuploidies (SCAs) in a cohort of 570 pregnancies |
| Q40053685 | The association between anticoagulation therapy, maternal characteristics, and a failed cfDNA test due to a low fetal fraction |
| Q39202434 | The benefits and limitations of cell-free DNA screening for 47, XXY (Klinefelter syndrome). |
| Q35879299 | The biology and diagnostic applications of fetal DNA and RNA in maternal plasma |
| Q46271940 | The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population |
| Q50776877 | The dysfunctional placenta epigenome: causes and consequences. |
| Q41202120 | The effect of chorionic villus sampling on the fraction of cell-free fetal DNA in maternal plasma |
| Q42643973 | The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review |
| Q34374066 | The feasibility study of non-invasive fetal trisomy 18 and 21 detection with semiconductor sequencing platform |
| Q33860369 | The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands |
| Q46529462 | The highly variable RH locus in nonwhite persons hampers RHD zygosity determination but yields more insight into RH-related evolutionary events |
| Q38584359 | The impact of digital DNA counting technologies on noninvasive prenatal testing |
| Q54708648 | The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. |
| Q48274405 | The influence of SNP-based chromosomal microarray and NIPT on the diagnostic yield in 10,000 fetuses with and without fetal ultrasound anomalies |
| Q78840671 | The ins and outs of fetal DNA in maternal plasma |
| Q64112101 | The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis |
| Q36176604 | The molecular genetics of blood group polymorphism |
| Q84511507 | The molecular genetics of blood group polymorphism |
| Q36055119 | The next 150 years of congenital adrenal hyperplasia |
| Q37672566 | The next-generation sequencing revolution and its impact on genomics |
| Q34514907 | The past and future of haemophilia: diagnosis, treatments, and its complications. |
| Q55269325 | The potential of liquid biopsies for the early detection of cancer. |
| Q36554628 | The prevention of thalassemia |
| Q40437073 | The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells |
| Q34272104 | The triple test as a screening technique for Down syndrome: reliability and relevance |
| Q35986418 | The tumor suppressor gene TP53: implications for cancer management and therapy |
| Q34377867 | The use of cffDNA in fetal sex determination during the first trimester of pregnancy of female DMD carriers |
| Q45998316 | The utilization of circulating cell-free fetal DNA testing and decrease in invasive diagnostic procedures: an institutional experience. |
| Q42917530 | Three-hour analysis of non-invasive foetal sex determination: application of Plexor chemistry |
| Q26995586 | Tracking fetal development through molecular analysis of maternal biofluids |
| Q58923877 | Transabdominal coelocentesis as early source of fetal DNA for chromosomal and molecular diagnosis |
| Q36411665 | Transrenal DNA testing: progress and perspectives |
| Q35221979 | Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. |
| Q40085419 | Tumor DNA: an emerging biomarker in head and neck cancer |
| Q38048368 | Universal screening for inherited metabolic diseases in the neonate (and the fetus). |
| Q54159132 | Unmethylated-maspin DNA in maternal plasma is associated with severe preeclampsia. |
| Q55311645 | Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. |
| Q60925942 | Use of pregnancy ultrasound before the 19th week scan: an analytical study based on the Icelandic Childbirth and Health Cohort |
| Q73592946 | Use of the Kleihauer test to detect fetal erythroblasts in the maternal circulation |
| Q38822505 | Using fetal cells for prenatal diagnosis: History and recent progress |
| Q33538996 | Using population-based data to predict the impact of introducing noninvasive prenatal diagnosis for Down syndrome. |
| Q35869114 | Utilization of Benchtop Next Generation Sequencing Platforms Ion Torrent PGM and MiSeq in Noninvasive Prenatal Testing for Chromosome 21 Trisomy and Testing of Impact of In Silico and Physical Size Selection on Its Analytical Performance. |
| Q52688329 | Validation of a SNP-based non-invasive prenatal test to detect the fetal 22q11.2 deletion in maternal plasma samples. |
| Q39641895 | Validation of combinatorial probe-anchor ligation-based sequencing as non-invasive prenatal test for trisomy at a central laboratory |
| Q34340985 | Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. |
| Q38410274 | Validation of two-channel sequencing-by-synthesis for noninvasive prenatal testing of fetal whole and partial chromosome aberrations |
| Q39235307 | Vanishing twin as a potential source of bias in non-invasive fetal sex determination: a case report |
| Q51039797 | Variability of ffDNA in maternal plasma does not prevent correct classification of trisomy 21 using MeDIP-qPCR methodology. |
| Q48339570 | Vox Sanguinis International Forum on application of fetal blood grouping: summary. |
| Q37631891 | WISECONDOR: detection of fetal aberrations from shallow sequencing maternal plasma based on a within-sample comparison scheme. |
| Q38209384 | What does next-generation sequencing mean for prenatal diagnosis? |
| Q35595108 | Whole genome bisulfite sequencing of cell-free DNA and its cellular contributors uncovers placenta hypomethylated domains |
| Q47949994 | Whole-genome fetal and maternal DNA methylation analysis using MeDIP-NGS for the identification of differentially methylated regions. |
| Q37333449 | Will the introduction of non-invasive prenatal testing for Down's syndrome undermine informed choice? |
| Q57839583 | Women’s and health professionals’ preferences for prenatal tests for Down syndrome: a discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests |
| Q41154655 | Working Towards a Reproducible Method for Quantifying Placental Syncytial Knots |
| Q34826830 | Y-chromosome DNA is present in the blood of female dogs suggesting the presence of fetal microchimerism |
| Q38911516 | Y-chromosome identification in circulating cell-free fetal DNA using surface plasmon resonance |
| Q54295517 | [First trimester fetal sex determination in maternal serum using real-time PCR]. |
| Q80380759 | [Immunohematologic surveillance of the pregnant woman and the new prevention policy of anti-RH1 allo-immunization] |
| Q83779100 | [Immunohematological surveillance of the pregnant woman: new prevention policy] |
| Q50542829 | [Management of feto-maternal red cell allo-immunizations]. |
| Q84093944 | [Non invasive diagnosis of fetal diseases by maternal blood tests] |
| Q87340257 | [Non-invasive fetal RHD genotyping: Validation of the method with 200 patients] |
| Q92092579 | [Noninvasive prenatal genetic testing in 6804 pregnant women aged less than 35 years with positive results in serum screening] |
| Q54645596 | [Prenatal determination of fetal RHD in maternal plasma: two-years experience of routine clinical use] |
| Q52881355 | [Prenatal diagnostics: current medical aspects]. |
| Q47191639 | cfDNA screening and diagnosis of monogenic disorders - where are we heading? |
| Q60929787 | deletion causes aberrations in length and end-motif frequencies in plasma DNA |
| Q34960254 | mRNA of placental origin is readily detectable in maternal plasma. |